NYSE:BMY - Bristol-Myers Squibb Stock Price, Price Target & More

Get Started

$52.77 +0.08 (+0.15 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$52.77

Today's Range$52.54 - $53.00

52-Week Range$49.96 - $70.05

Volume3.74 million shs

Average Volume7.83 million shs

Market Capitalization$86.12 billion

P/E Ratio17.53

Dividend Yield3.04%

Beta0.99

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:BMY

CUSIP11012210

Webwww.bms.com

Phone212-546-4000

Debt

Debt-to-Equity Ratio0.45

Current Ratio1.52

Quick Ratio1.39

Price-To-Earnings

Trailing P/E Ratio17.53

Forward P/E Ratio15.43

P/E Growth1.32

Sales & Book Value

Annual Sales$20.78 billion

Price / Sales4.15

Cash Flow$3.5251 per share

Price / Cash14.97

Book Value$7.90 per share

Price / Book6.68

Profitability

EPS (Most Recent Fiscal Year)$3.01

Net Income$1.01 billion

Net Margins4.37%

Return on Equity37.56%

Return on Assets15.27%

Miscellaneous

Employees23,700

Outstanding Shares1,634,540,000

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, March 1st. Stockholders of record on Friday, April 6th will be paid a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.09. The biopharmaceutical company had revenue of $5.19 billion for the quarter, compared to analysts' expectations of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 EPS. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $3.35-3.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.26.

What price target have analysts set for BMY?

19 equities research analysts have issued 1 year price targets for Bristol-Myers Squibb's stock. Their predictions range from $47.00 to $78.00. On average, they expect Bristol-Myers Squibb's stock price to reach $62.6519 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in April. As of April 13th, there was short interest totalling 14,317,338 shares, an increase of 28.5% from the March 30th total of 11,139,095 shares. Based on an average daily trading volume, of 7,952,211 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.9% of the company's stock are sold short.

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:

Dr. Giovanni Caforio, Chairman & CEO (Age 53)
Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 58)
Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 57)
Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)

Has Bristol-Myers Squibb been receiving favorable news coverage?

News headlines about BMY stock have trended positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.30 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Northern Trust Corp (1.40%), Loomis Sayles & Co. L P (0.82%), Legal & General Group Plc (0.49%), Massachusetts Financial Services Co. MA (0.41%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Northern Trust Corp, Swiss National Bank, Prudential Financial Inc., OppenheimerFunds Inc., Manning & Napier Group LLC, Legal & General Group Plc and State of Tennessee Treasury Department. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was bought by a variety of institutional investors in the last quarter, including Argent Capital Management LLC, Rock Springs Capital Management LP, Massachusetts Financial Services Co. MA, DekaBank Deutsche Girozentrale, Rockefeller Capital Management L.P., Mackay Shields LLC, Summit Trail Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $52.77.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $86.12 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		729 (Vote Outperform)
Underperform Votes:		705 (Vote Underperform)
Total Votes:		1,434

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $62.6519, suggesting that the stock has a possible upside of 18.73%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.37	2.37	2.44	2.47
Ratings Breakdown:	0 Sell Rating(s) 12 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$62.6519	$64.2144	$66.4615	$64.50
Price Target Upside:	18.73% upside	23.39% upside	3.65% downside	7.61% upside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/21/2018	UBS	Downgrade	Buy ➝ Neutral	$57.00	Low
4/27/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$65.00 ➝ $55.00	Low
4/27/2018	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform		Low
4/26/2018	Credit Suisse Group	Set Price Target	Hold	$58.00	Low
4/20/2018	Cowen	Reiterated Rating	Hold	$60.00	Low
4/17/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$68.00 ➝ $61.00	Low
4/17/2018	William Blair	Reiterated Rating	Outperform		High
4/17/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$54.08 ➝ $58.00	High
4/13/2018	Jefferies Group	Reiterated Rating	Hold	$66.00	Low
3/21/2018	Argus	Reiterated Rating	Buy	$75.00 ➝ $66.43	Low
3/20/2018	JPMorgan Chase & Co.	Set Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00	Low
2/28/2018	DZ Bank	Downgrade	Buy ➝ Hold		High
2/16/2018	Citigroup	Set Price Target	Buy	$78.00	Low
2/6/2018	Leerink Swann	Boost Price Target	Outperform ➝ Positive	$71.00 ➝ $76.00	Medium
10/30/2017	SunTrust Banks	Upgrade	Hold ➝ Buy		N/A
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$60.00	N/A
9/12/2017	Hilliard Lyons	Downgrade	Long-term Buy ➝ Neutral	$65.00	Low
9/7/2017	Goldman Sachs Group	Reiterated Rating	Buy	$62.00 ➝ $65.00	Low
7/17/2017	Deutsche Bank	Set Price Target	Hold	$54.00 ➝ $55.00	Low
4/25/2017	Robert W. Baird	Initiated Coverage	Outperform		Low
2/9/2017	Gabelli	Reiterated Rating	Buy		N/A
1/8/2017	Evercore ISI	Reiterated Rating	Hold	$55.00	N/A
8/11/2016	Berenberg Bank	Downgrade	Buy ➝ Hold	$80.00 ➝ $70.00	N/A
8/11/2016	Sanford C. Bernstein	Reiterated Rating	Market Perform	$79.00 ➝ $65.00	N/A

(Data available from 5/26/2016 forward)

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.26
2019 EPS Consensus Estimate: $3.46

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$0.74	$0.88	$0.83
Q2 2018	3	$0.76	$0.88	$0.83
Q3 2018	3	$0.77	$0.86	$0.82
Q4 2018	3	$0.76	$0.84	$0.79
Q1 2019	1	$0.83	$0.83	$0.83
Q2 2019	1	$0.85	$0.85	$0.85
Q3 2019	1	$0.88	$0.88	$0.88
Q4 2019	1	$0.90	$0.90	$0.90

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/25/2018		$0.86					N/A
4/26/2018	Q1 2018	$0.85	$0.94	$5.2509 billion	$5.1930 billion	View	N/A
2/5/2018	Q4 2017	$0.67	$0.68	$5.3479 billion	$5.4490 billion	View	Listen
10/26/2017	Q3 2017	$0.77	$0.75	$5.1957 billion	$5.2540 billion	View	N/A
7/27/2017	Q2 2017	$0.73	$0.74	$5.0876 billion	$5.1440 billion	View	N/A
4/27/2017	Q1 2017	$0.72	$0.84	$4.7485 billion	$4.9290 billion	View	N/A
1/26/2017	Q416	$0.67	$0.63	$5.14 billion	$5.24 billion	View	N/A
10/27/2016	Q316	$0.65	$0.77	$4.76 billion	$4.83 billion	View	Listen
7/28/2016	Q216	$0.67	$0.69	$4.60 billion	$4.90 billion	View	Listen
4/28/2016	Q116	$0.65	$0.74	$4.19 billion	$4.39 billion	View	Listen
1/28/2016	Q415	$0.28	$0.38	$4.07 billion	$4.29 billion	View	Listen
10/27/2015	Q315	$0.35	$0.39	$3.83 billion	$4.07 billion	View	Listen
7/23/2015	Q215	$0.36	$0.53	$3.68 billion	$4.16 billion	View	Listen
4/28/2015	Q115	$0.50	$0.71	$3.80 billion	$4.04 billion	View	N/A
1/27/2015	Q414	$0.40	$0.46	$4.02 billion	$4.26 billion	View	N/A
10/24/2014	Q314	$0.42	$0.45	$3.80 billion	$3.92 billion	View	Listen
7/24/2014	Q214	$0.44	$0.48	$3.85 billion	$3.89 billion	View	Listen
4/29/2014	Q114	$0.43	$0.46	$3.89 billion	$3.81 billion	View	Listen
1/24/2014	Q413	$0.43	$0.53	$4.30 billion	$4.44 billion	View	Listen
10/23/2013	Q313	$0.44	$0.46	$4.02 billion	$4.07 billion	View	Listen
7/25/2013	Q2 2013	$0.45	$0.44	$4.07 billion	$4.05 billion	View	Listen
4/25/2013	Q1 2013	$0.41	$0.41	$3.88 billion	$3.83 billion	View	Listen
1/24/2013	Q4 2012	$0.42	$0.47	$4.14 billion	$4.19 billion	View	Listen
10/24/2012		$0.42	$0.41			View	N/A
7/25/2012		$0.48	$0.48			View	N/A
4/26/2012		$0.64	$0.64			View	N/A
1/26/2012		$0.55	$0.53			View	N/A
10/27/2011		$0.58	$0.61			View	N/A
7/28/2011		$0.55	$0.56			View	N/A
4/28/2011		$0.53	$0.58			View	N/A
1/27/2011		$0.48	$0.47			View	N/A

(Earnings results data provided by Zacks Investment Research)

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.03%. BMY's most recent quarterly dividend payment was Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.

Most Recent Dividend:	5/1/2018
Annual Dividend:	$1.60
Dividend Yield:	3.03%
Dividend Growth:	2.70% (3 Year Average)
Payout Ratio(s):	53.16% (Trailing 12 Months of Earnings) 46.78% (Based on This Year's Estimates) 43.96% (Based on Next Year's Estimates) 45.39% (Based on Cash Flow)
Track Record:	8 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/1/2018	quarterly	$0.40	2.43568275232151%	4/5/2018	4/6/2018	5/1/2018
12/7/2017	quarterly	$0.40	2.56%	1/4/2018	1/5/2018	2/1/2018
9/13/2017	quarterly	$0.39	2.49%	10/5/2017	10/6/2017	11/1/2017
6/13/2017	quarterly	$0.39	2.86%	7/5/2017	7/7/2017	8/1/2017
3/2/2017	quarterly	$0.39	2.72%	4/5/2017	4/7/2017	5/1/2017
12/8/2016	quarterly	$0.39	2.73%	1/4/2017	1/6/2017	2/1/2017
8/3/2016	quarterly	$0.38	2.02%	10/5/2016	10/7/2016	11/1/2016
6/7/2016	quarterly	$0.38	2.07%	6/29/2016	7/1/2016	8/1/2016
3/3/2016	quarterly	$0.38	2.35%	3/30/2016	4/1/2016	5/2/2016
12/8/2015	quarterly	$0.38	2.22%	12/30/2015	1/4/2016	2/1/2016
9/17/2015	quarterly	$0.37	2.3%	9/30/2015	10/2/2015	11/2/2015
6/16/2015	quarterly	$0.37	2.23%	7/1/2015	7/6/2015	8/3/2015
3/2/2015	quarterly	$0.37	2.39%	4/1/2015	4/6/2015	5/1/2015
12/9/2014	quarterly	$0.37	2.5%	12/30/2014	1/2/2015	2/2/2015
9/16/2014	quarterly	$0.36	2.83%	10/1/2014	10/3/2014	11/3/2014
6/17/2014	quarterly	$0.36	3%	7/1/2014	7/3/2014	8/1/2014
3/3/2014	quarterly	$0.36	2.55%	4/2/2014	4/4/2014	5/1/2014
12/19/2013	quarterly	$0.36	2.7%	12/31/2013	1/3/2014	2/3/2014
9/17/2013	quarterly	$0.35	2.95%	10/2/2013	10/4/2013	11/1/2013
6/19/2013	quarterly	$0.35	3.14%	7/2/2013	7/5/2013	8/1/2013
3/7/2013	quarterly	$0.35	3.74%	4/3/2013	4/5/2013	5/1/2013
12/4/2012	quarterly	$0.35			1/4/2013	2/1/2013

(Data available from 1/1/2013 forward)

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 71.29%

Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2018	Dinesh C Paliwal	Director	Buy	4,770	$52.40	$249,948.00	8,027
12/15/2017	Theodore R Samuels II	Director	Buy	4,000	$62.30	$249,200.00	22,000
12/12/2017	Thomas J Jr. Lynch	EVP	Sell	5,300	$63.24	$335,172.00	9,251
12/4/2017	Sandra Leung	EVP	Sell	156,582	$63.37	$9,922,601.34	584,373
9/6/2017	Joseph C Caldarella	SVP	Sell	9,340	$60.00	$560,400.00	46,297
8/2/2017	Theodore R Samuels II	Director	Buy	6,000	$55.94	$335,640.00	18,000
4/7/2017	Lamberto Andreotti	Director	Sell	34,000	$53.26	$1,810,840.00	952,571
3/28/2017	Lamberto Andreotti	Director	Sell	34,000	$56.17	$1,909,780.00	986,112
3/27/2017	Lamberto Andreotti	Director	Sell	17,000	$56.14	$954,380.00	986,112
3/17/2017	Louis S Schmukler	Insider	Sell	5,000	$56.49	$282,450.00	21,483
3/15/2017	Joseph C Caldarella	SVP	Sell	8,096	$57.29	$463,819.84	55,637
3/6/2017	Sandra Leung	EVP	Sell	92,405	$57.02	$5,268,933.10	488,063
2/27/2017	Theodore R Samuels II	Director	Buy	12,000	$56.77	$681,240.00	12,000
9/8/2016	Lamberto Andreotti	Director	Sell	21,600	$56.87	$1,228,392.00	334,499
8/25/2016	Lamberto Andreotti	Director	Sell	23,200	$59.17	$1,372,744.00	364,999
7/8/2016	Lamberto Andreotti	Director	Sell	23,200	$74.45	$1,727,240.00	380,099
6/28/2016	Lamberto Andreotti	Director	Sell	23,200	$72.14	$1,673,648.00	403,094
6/14/2016	John E Elicker	SVP	Sell	11,820	$72.69	$859,195.80	55,011
5/20/2016	Charles A Bancroft	CFO	Sell	30,201	$70.79	$2,137,928.79	184,694
5/16/2016	Joseph C Caldarella	SVP	Sell	3,519	$72.47	$255,021.93	55,238
5/6/2016	Sandra Leung	EVP	Sell	72,544	$70.39	$5,106,372.16	444,507
5/5/2016	Lamberto Andreotti	Director	Sell	23,200	$70.54	$1,636,528.00	425,194
5/3/2016	Giovanni Caforio	CEO	Sell	34,594	$71.31	$2,466,898.14	132,263
5/2/2016	Autenried Paul Von	SVP	Sell	37,258	$71.93	$2,679,967.94	128,463
5/2/2016	Lamberto Andreotti	Director	Sell	234,720	$71.88	$16,871,673.60	536,794
5/2/2016	Louis S Schmukler	Insider	Sell	22,218	$71.95	$1,598,585.10	21,971
4/5/2016	Lamberto Andreotti	Director	Sell	23,200	$65.90	$1,528,880.00	453,094
4/4/2016	Lamberto Andreotti	Director	Sell	11,600	$65.79	$763,164.00	453,094
3/9/2016	Lamberto Andreotti	Director	Sell	23,200	$65.71	$1,524,472.00	381,254
3/8/2016	Lewis B Campbell	Director	Sell	2,500	$66.00	$165,000.00	2,500
3/4/2016	Joseph C Caldarella	SVP	Sell	12,962	$64.64	$837,863.68	46,322
2/17/2016	Giovanni Caforio	CEO	Sell	12,040	$63.58	$765,503.20	76,738
2/17/2016	Sandra Leung	EVP	Sell	10,152	$63.57	$645,362.64	309,547
2/12/2016	Lamberto Andreotti	Director	Sell	23,200	$59.61	$1,382,952.00	392,854
1/5/2016	Lamberto Andreotti	Director	Sell	23,200	$67.56	$1,567,392.00	310,424
1/4/2016	Lamberto Andreotti	Director	Sell	11,600	$66.93	$776,388.00	310,424
12/15/2015	Lamberto Andreotti	Director	Sell	23,200	$69.03	$1,601,496.00	332,852
11/20/2015	Lamberto Andreotti	Director	Sell	23,200	$67.39	$1,563,448.00	456,052
10/6/2015	Lamberto Andreotti	Director	Sell	23,200	$60.86	$1,411,952.00	524,252
9/3/2015	Lamberto Andreotti	Director	Sell	23,200	$59.40	$1,378,080.00	546,874
6/4/2015	Joseph C Caldarella	SVP	Sell	16,972	$65.71	$1,115,230.12
3/16/2015	Francis M Cuss	EVP	Sell	114,666	$67.81	$7,775,501.46
3/16/2015	Louis S Schmukler	Insider	Sell	12,000	$66.96	$803,520.00
2/17/2015	Sandra Leung	General Counsel	Sell	11,746	$60.39	$709,340.94
2/12/2015	Samuel J Moed	SVP	Sell	3,880	$59.26	$229,928.80
2/6/2015	Samuel J Moed	SVP	Sell	21,478	$60.15	$1,291,901.70
1/29/2015	Lamberto Andreotti	CEO	Sell	90,246	$61.14	$5,517,640.44
1/29/2015	Lewis B Campbell	Director	Sell	2,500	$60.89	$152,225.00
1/29/2015	Louis S Schmukler	Insider	Sell	5,250	$60.73	$318,832.50
12/5/2014	Lamberto Andreotti	CEO	Sell	75,000	$60.31	$4,523,250.00
10/24/2014	Lamberto Andreotti	CEO	Sell	50,000	$53.00	$2,650,000.00
10/6/2014	Lamberto Andreotti	CEO	Sell	50,000	$50.99	$2,549,500.00
9/16/2014	Francis M Cuss	EVP	Sell	63,667	$50.77	$3,232,373.59
9/15/2014	Giovanni Caforio	COO	Sell	26,691	$49.87	$1,331,080.17
9/10/2014	Joseph C Caldarella	SVP	Sell	7,415	$51.03	$378,387.45
9/8/2014	Lamberto Andreotti	CEO	Sell	50,000	$51.05	$2,552,500.00
8/19/2014	Autenried Paul Von	SVP	Sell	20,000	$49.89	$997,800.00
7/29/2014	Charles A Bancroft	CFO	Sell	67,621	$51.06	$3,452,728.26
7/28/2014	Samuel J Moed	SVP	Sell	25,752	$49.32	$1,270,088.64
3/13/2014	Joseph Caldarella	SVP	Sell	9,137	$55.20	$504,362.40	68,965
3/10/2014	Lamberto Andreotti	CEO	Sell	100,000	$55.52	$5,552,000.00	630,783
3/10/2014	Louis Schmukler	Insider	Sell	8,799	$55.81	$491,072.19	8,861
3/5/2014	James Cornelius	Director	Sell	100,000	$55.82	$5,582,000.00	273,393
2/28/2014	Louis Schmukler	Insider	Sell	6,088	$54.49	$331,735.12	14,696
2/24/2014	Giovanni Caforio	EVP	Sell	41,563	$54.44	$2,262,689.72	49,753
2/19/2014	John Elicker	SVP	Sell	9,534	$54.22	$516,933.48	32,740
2/18/2014	Francis Cuss	EVP	Sell	29,800	$54.61	$1,627,378.00	207,237
2/14/2014	Charles Bancroft	CFO	Sell	52,963	$54.35	$2,878,539.05	77,303
2/14/2014	Sandra Leung	General Counsel	Sell	10,490	$54.28	$569,397.20	195,855
2/11/2014	Lamberto Andreotti	CEO	Sell	86,075	$52.66	$4,532,709.50	500,487
2/6/2014	Joseph Caldarella	SVP	Sell	35,471	$48.90	$1,734,531.90	59,355
2/5/2014	Lewis Campbell	Director	Sell	2,500	$48.28	$120,700.00
2/4/2014	James Cornelius	Director	Sell	100,000	$48.90	$4,890,000.00	373,393
7/29/2013	James M Cornelius	Director	Sell	5,000	$43.81	$219,050.00
6/10/2013	Autenried Paul Von	SVP	Sell	25,000	$47.24	$1,181,000.00
6/6/2013	Joseph C Caldarella	SVP	Sell	26,275	$46.53	$1,222,575.75
6/5/2013	John E Elicker	SVP	Sell	25,997	$46.33	$1,204,441.01
6/4/2013	Lamberto Andreotti	CEO	Sell	100,000	$47.74	$4,774,000.00
6/4/2013	Samuel J Moed	SVP	Sell	58,898	$47.38	$2,790,587.24
6/3/2013	Elliot Sigal	EVP	Sell	83,647	$48.18	$4,030,112.46
5/31/2013	Beatrice J Cazala	EVP	Sell	91,282	$47.00	$4,290,254.00
5/31/2013	Giovanni Caforio	Insider	Sell	10,538	$47.06	$495,918.28
5/30/2013	Beatrice J Cazala	EVP	Sell	22,000	$47.00	$1,034,000.00
5/28/2013	Charles A Bancroft	CFO	Sell	25,000	$48.68	$1,217,000.00
5/28/2013	James M Cornelius	Director	Sell	100,000	$47.61	$4,761,000.00
5/23/2013	Beatrice J Cazala	EVP	Sell	96,000	$46.99	$4,511,040.00
5/23/2013	Giovanni Caforio	Insider	Sell	26,647	$46.29	$1,233,489.63
5/17/2013	James M Cornelius	Director	Sell	225,996	$42.99	$9,715,568.04
5/8/2013	James M Cornelius	Director	Sell	20,000	$39.85	$797,000.00
5/2/2013	James M Cornelius	Director	Sell	20,000	$39.76	$795,200.00
4/11/2013	James M Cornelius	Director	Sell	20,000	$41.15	$823,000.00
3/13/2013	James M Cornelius	Director	Sell	20,000	$38.18	$763,600.00
3/13/2013	John E Elicker	SVP	Sell	3,409	$38.51	$131,280.59
2/27/2013	Giovanni Caforio	Insider	Sell	12,150	$37.08	$450,522.00
2/26/2013	James M Cornelius	Director	Sell	20,000	$36.58	$731,600.00
1/17/2013	James M Cornelius	Director	Sell	20,000	$34.33	$686,600.00
12/28/2012	James M Cornelius	Director	Sell	20,000	$32.06	$641,200.00
10/3/2012	James M Cornelius	Director	Sell	20,000	$33.71	$674,200.00
8/10/2012	James M Cornelius	Director	Sell	10,000	$31.81	$318,100.00

(Data available from 1/1/2013 forward)

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:

Date	Headline
	Label Expansion May Boost Opdivo’s Revenues in 2018 finance.yahoo.com - May 25 at 5:21 PM
	Idera to collaborate with Bristol-Myers on study of IMO-2125/Yervoy combo in melanoma; shares up 4% premarket seekingalpha.com - May 24 at 5:22 PM
	Interesting BMY Put And Call Options For July 6th www.nasdaq.com - May 24 at 5:22 PM
	BMS-986231 (Bristol-Myers Squibb/Ligand) Drug Overview 2018: A Second-Generation Prodrug That Chemically Breaks Down to Produce Nitroxyl (HNO) and an Inactive Byproduct ... www.businesswire.com - May 24 at 8:40 AM
	Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights finance.yahoo.com - May 24 at 8:40 AM
	Bristol-Myers Squibb (BMY) Rating Lowered to Hold at UBS www.americanbankingnews.com - May 21 at 11:05 AM
	$5.40 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter www.americanbankingnews.com - May 21 at 3:04 AM
	3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara's Immunotherapy Data seekingalpha.com - May 20 at 9:00 AM
	$0.86 EPS Expected for Bristol-Myers Squibb (BMY) This Quarter www.americanbankingnews.com - May 19 at 1:24 PM
	Global Bipolar Disorder Market Growth Opportunities: Sumitomo Dainippon Pharma Co., Allergan, Bristol-Myers Squibb Company www.marketwatch.com - May 18 at 9:46 AM
	Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO www.streetinsider.com - May 17 at 5:14 PM
	Immunomedics Announces Positive Phase 2 Results finance.yahoo.com - May 17 at 5:14 PM
	Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 finance.yahoo.com - May 16 at 5:21 PM
	Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference finance.yahoo.com - May 15 at 8:42 AM
	Exploring Bristol-Myers Squibb’s Financial Performance finance.yahoo.com - May 15 at 8:42 AM
	How Bristol-Myers Squibb’s Key Products Performed in 1Q18 finance.yahoo.com - May 14 at 5:13 PM
	What’s Bristol-Myers Squibb’s Business Strategy? finance.yahoo.com - May 14 at 5:13 PM
	Bristol-Myers Squibb (BMY) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - May 13 at 5:31 PM
	Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) Drug Overview 2017/18-2026: An Orally Available Factor Xa Inhibitor Indicated for the Prevention of Venous Thromboembolsim ... www.businesswire.com - May 11 at 5:35 PM
	Label Expansion May Boost Keytruda’s Revenue Prospects in 2018 finance.yahoo.com - May 11 at 9:31 AM
	Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes www.prnewswire.com - May 11 at 7:30 AM
	How Merck’s Animal Health Segment Did in 1Q18 finance.yahoo.com - May 10 at 8:45 AM
	Why Bristol-Myers Squibb Stock Crashed in April www.fool.com - May 9 at 12:58 PM
	Q4 2018 EPS Estimates for Bristol-Myers Squibb Raised by SunTrust Banks (BMY) www.americanbankingnews.com - May 9 at 9:06 AM
	See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. finance.yahoo.com - May 9 at 8:40 AM
	New 52-Week Low Could Prompt More Insider Buying At BMY www.nasdaq.com - May 8 at 5:19 PM
	Q2 2018 EPS Estimates for Bristol-Myers Squibb Lifted by Analyst (BMY) www.americanbankingnews.com - May 8 at 5:56 AM
	Bristol-Myers Squibb Co. (BMY) PT Lowered to $69 at SunTrust Robinson Humphrey www.streetinsider.com - May 7 at 9:31 AM
	Allergan’s International Business in 1Q18 finance.yahoo.com - May 7 at 9:31 AM
	As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars finance.yahoo.com - May 5 at 8:39 AM
	BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment ... www.reuters.com - May 4 at 8:29 AM
	Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination ... www.streetinsider.com - May 4 at 8:29 AM
	BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors www.reuters.com - May 4 at 8:29 AM
	Bristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.38 Billion www.americanbankingnews.com - May 4 at 4:40 AM
	Bristol-Myers Squibb (BMY) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - May 3 at 10:32 PM
	Bristol-Myers to team up with Flatiron Health for an additional three years seekingalpha.com - May 3 at 8:39 AM
	Global Polycystic Ovarian Syndrome Treatment Market Competitive landscape: Bristol-Myers Squibb Company www.marketwatch.com - May 3 at 8:39 AM
	BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement www.reuters.com - May 2 at 5:13 PM
	Bristol-Myers Squibb (BMY), Flatiron Health Expand Collaboration with Three-Year Agreement www.streetinsider.com - May 2 at 5:13 PM
	Comparing BMY’s and LLY’s Valuation finance.yahoo.com - May 2 at 5:13 PM
	The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda finance.yahoo.com - May 2 at 5:13 PM
	Dinesh C. Paliwal Buys 4,770 Shares of Bristol-Myers Squibb (BMY) Stock www.americanbankingnews.com - May 2 at 4:38 PM
	Eli Lilly Expected to Report a Modest Rise in Revenues in 2018 finance.yahoo.com - May 2 at 8:26 AM
	$0.85 Earnings Per Share Expected for Bristol-Myers Squibb (BMY) This Quarter www.americanbankingnews.com - May 2 at 1:22 AM
	How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer www.bizjournals.com - May 1 at 5:14 PM
	Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop finance.yahoo.com - May 1 at 5:14 PM
	How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer finance.yahoo.com - May 1 at 5:14 PM
	Ramp Up In Opdivo And Eliquis Sales Bolsters Bristol-Myers Squibb's Q1 Earnings www.forbes.com - April 30 at 4:10 PM
	3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorm's ALS Adventure Moves Forward seekingalpha.com - April 30 at 9:52 AM
	Q2 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By William Blair www.americanbankingnews.com - April 30 at 2:14 AM

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff